Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
- PMID: 33580167
- PMCID: PMC7880638
- DOI: 10.1038/s41423-021-00641-8
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.Cell Mol Immunol. 2021 Apr;18(4):1061-1063. doi: 10.1038/s41423-021-00648-1. Epub 2021 Feb 25. Cell Mol Immunol. 2021. PMID: 33633321 Free PMC article. No abstract available.
-
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7. N Engl J Med. 2021. PMID: 33826816 Free PMC article. No abstract available.
-
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7. Virol J. 2021. PMID: 33435994 Free PMC article.
-
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7. mBio. 2021. PMID: 34872349 Free PMC article.
-
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8. Nature. 2021. PMID: 34237773
Cited by
-
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.Adv Sci (Weinh). 2022 Apr;9(11):e2105378. doi: 10.1002/advs.202105378. Epub 2022 Feb 10. Adv Sci (Weinh). 2022. PMID: 35142444 Free PMC article.
-
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2106433118. doi: 10.1073/pnas.2106433118. Proc Natl Acad Sci U S A. 2021. PMID: 34470866 Free PMC article.
-
COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.Arch Virol. 2022 Sep;167(9):1773-1783. doi: 10.1007/s00705-022-05495-7. Epub 2022 Jun 20. Arch Virol. 2022. PMID: 35723757 Free PMC article. Review.
-
Clinical characteristics of COVID-19 patients in Xiaogan, China: comparison between recent imported cases and earlier local cases.Am J Transl Res. 2021 Oct 15;13(10):11999-12005. eCollection 2021. Am J Transl Res. 2021. PMID: 34786134 Free PMC article.
-
A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic.Viruses. 2021 Jun 9;13(6):1098. doi: 10.3390/v13061098. Viruses. 2021. PMID: 34207490 Free PMC article.
References
-
- Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020.2012.2021.20248640, 10.1101/2020.12.21.20248640 (2020).
-
- Kemp, S. et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70. bioRxiv, 2020.2012.2014.422555, 10.1101/2020.12.14.422555 (2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
